PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGSS.L Regulatory News (GSS)

  • There is currently no data for GSS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tender Offer: Publication of Circular

19 Jul 2018 13:01

RNS Number : 1953V
Genesis Emerging Markets Fund Ld
19 July 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

19 July 2018

 

Genesis Emerging Markets Fund Limited (the "Company")

Tender Offer for up to 10 per cent. of the issued Share Capital of the CompanyPublication of Circular

Further to the Company's announcement on 27 June 2018, the Company has today released a circular (the "Circular") containing both: (i) details of the Tender Offer (as defined below) for up to 10 per cent. of the issued share capital of the Company to be put forward to its Shareholders, other than certain Overseas Shareholders (the "Eligible Shareholders") by J.P. Morgan Securities plc, which conducts its UK investment banking services as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"); and (ii) a Notice of Extraordinary General Meeting to be held at 11.00 a.m. on 15 August 2018 at 60 Victoria Embankment, London EC4Y 0AP (the Extraordinary General Meeting") seeking Shareholder approval of a Tender Offer.

The Tender Offer is conditional upon the Company receiving the consent of its Shareholders at the Extraordinary General Meeting. The Circular sets out the background to and reasons for the Tender Offer and the terms and conditions to which it is subject. Terms used in this announcement but not defined herein shall have the same meaning as in the Circular.

Reasons for the Tender Offer

The tender offer (the "Tender Offer") will be for up to 10 per cent. of the Company's issued share capital (the "Shares") (excluding any Shares held in treasury) and is being made by J.P. Morgan Cazenove. J.P. Morgan Cazenove will, as principal, purchase the Shares that have been validly tendered, on and subject to the terms and conditions of the Tender Offer, by means of on-market purchases and, following the completion of all those purchases, sell them to the Company.

The Company's Board of directors (the "Board") has arranged for the Tender Offer to be made to enable those Eligible Shareholders who wish to realise a portion of their investment in the Company to do so, whilst ensuring that continuing Shareholders who do not wish to tender their Shares are not disadvantaged and at the same time introducing some mechanisms to seek to produce better shareholder returns in the future.

Pricing and terms of the Tender Offer

The price per Share at which Shares will be acquired by J.P. Morgan Cazenove under the Tender Offer will be equal to 96.5 per cent. of the Net Asset Value per Share of the Company as at the close of business on 16 August 2018. Prior to that date, it is intended that the Company will have realised a sufficient proportion of its investment portfolio to fund the Company's repurchase under the Repurchase Agreement of the Shares acquired by J.P. Morgan Cazenove under the Tender Offer. Further details of the calculation of the Tender Price are set out in the Circular.

Under the terms of the Tender Offer, Eligible Shareholders will be able to tender up to 10 per cent. of the Shares registered in their name on the Register as at the Record Date (the "Basic Entitlement"), rounded down to the nearest whole number of Shares. Shareholders will also have the option to tender additional Shares to the extent that other Shareholders tender less than their Basic Entitlement. Any such excess tenders will be satisfied pro rata in proportion to the amount tendered in excess of the Basic Entitlement (rounded down to the nearest whole number of Shares).

The Tender Offer will be available to Eligible Shareholders on the Register as at the Record Date (as defined in the timetable below).

The maximum number of Shares to be acquired under the Tender Offer is 13,496,306 Shares, representing 10 per cent. of the Shares in issue (excluding any Shares held in treasury) as at 17 July 2018 (the "Latest Practicable Date") (the "Available Shares").

An Eligible Shareholder tendering up to its Basic Entitlement will have its tender satisfied in full. Any Eligible Shareholder tendering more than its Basic Entitlement ("Excess Applications") will have its Excess Application satisfied if there are sufficient remaining Available Shares. Such Available Shares shall be apportioned to Eligible Shareholders pro rata to their Excess Applications should other Eligible Shareholders not tender the full amount of their Basic Entitlement and as a result of certain Overseas Shareholders not being permitted to participate in the Tender Offer.

Shares which are tendered for acceptance under the Tender Offer may not be withdrawn or sold, transferred, charged or otherwise disposed of.

The timing for settlement of the consideration to which any Eligible Shareholder is entitled under the Tender Offer will take into account the period required to realise investments to fund the repurchase of Shares under the Repurchase Agreement and the time for the Company to receive the proceeds of such realisations.

Expected timetable of events

Latest time and date for receipt of Tender Forms and TTE Instructions

1.00 p.m. on 13 August 2018

Record Date for Tender Offer

6.00 p.m. on 13 August 2018

Latest time and date for receipt of Forms of Proxy for the Extraordinary General Meeting

11.00 a.m. on 13 August 2018

Extraordinary General Meeting

11.00 a.m. on 15 August 2018

Results of Extraordinary General Meeting announced

15 August 2018

Results of Tender Offer announced

15 August 2018

NAV Determination Date (being the date of the NAV on which the Tender Price is based)

16 August 2018

Final Tender Price and repurchase date for successfully tendered Shares announced

17 August 2018

Settlement through CREST of, and despatch of cheques for, the Tender Offer consideration, as appropriate

by 3 September 2018

Despatch of balance share certificates and crediting of CREST accounts with Shares not purchased

by 3 September 2018

All references are to London time.

Posting of Circular

The Circular, which contains the full terms and conditions of the Tender Offer, instructions to Eligible Shareholders on how to tender their Shares should they choose to do so, together with the tender form (where relevant), is being posted to Eligible Shareholders.

A copy of the Circular will shortly be available to view on the Company's website at

https://www.genesisemf.com/

Enquiries:

Jonathan Snow - 020 7201 7200 - Genesis Investment Management, LLP

William H. S. Simmonds - 020 7742 4000 - J.P. Morgan Cazenove

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TENSFSFEUFASESW
Date   Source Headline
20th May 202011:33 amRNSNet Asset Value(s)
19th May 202010:57 amRNSNet Asset Value(s)
18th May 202010:48 amRNSNet Asset Value(s)
15th May 202011:12 amRNSNet Asset Value(s)
14th May 20201:17 pmRNSAvailability of Monthly Factsheet
14th May 202010:29 amRNSNet Asset Value(s)
13th May 202012:21 pmRNSAppointment of Joint Corporate Broker
13th May 202010:36 amRNSNet Asset Value(s)
12th May 202010:37 amRNSNet Asset Value(s)
11th May 202010:27 amRNSNet Asset Value(s)
7th May 202010:52 amRNSNet Asset Value(s)
6th May 202010:54 amRNSNet Asset Value(s)
5th May 202011:04 amRNSNet Asset Value(s)
4th May 20201:32 pmRNSNet Asset Value(s)
4th May 202012:53 pmRNSNet Asset Value(s)
1st May 20202:28 pmRNSNet Asset Value(s)
30th Apr 20205:25 pmRNSTotal Voting Rights
30th Apr 202010:54 amRNSNet Asset Value(s)
29th Apr 202011:37 amRNSNet Asset Value(s)
28th Apr 202011:07 amRNSNet Asset Value(s)
27th Apr 20201:04 pmRNSDisclosure of rights attached to equity shares
27th Apr 202010:54 amRNSNet Asset Value(s)
24th Apr 202010:42 amRNSNet Asset Value(s)
23rd Apr 202010:57 amRNSNet Asset Value(s)
22nd Apr 202011:47 amRNSNet Asset Value(s)
21st Apr 202011:02 amRNSNet Asset Value(s)
20th Apr 202011:47 amRNSNet Asset Value(s)
17th Apr 202010:42 amRNSNet Asset Value(s)
16th Apr 202011:27 amRNSNet Asset Value(s)
15th Apr 202012:12 pmRNSNet Asset Value(s)
15th Apr 202010:28 amRNSAvailability of Monthly Factsheet
14th Apr 202011:17 amRNSNet Asset Value(s)
9th Apr 202010:47 amRNSNet Asset Value(s)
8th Apr 202012:03 pmRNSNet Asset Value(s)
7th Apr 202011:31 amRNSNet Asset Value(s)
6th Apr 202011:03 amRNSNet Asset Value(s)
3rd Apr 202011:33 amRNSNet Asset Value(s)
2nd Apr 202010:32 amRNSNet Asset Value(s)
1st Apr 20204:29 pmRNSEdison review on Genesis Emerging Markets Fund
1st Apr 20201:27 pmRNSNet Asset Value(s)
31st Mar 202011:52 amRNSNet Asset Value(s)
30th Mar 202012:18 pmRNSNet Asset Value(s)
27th Mar 202012:06 pmRNSNet Asset Value(s)
26th Mar 202011:32 amRNSNet Asset Value(s)
25th Mar 202011:31 amRNSNet Asset Value(s)
24th Mar 202012:42 pmRNSNet Asset Value(s)
23rd Mar 202012:08 pmRNSNet Asset Value(s)
20th Mar 202012:03 pmRNSNet Asset Value(s)
19th Mar 202011:07 amRNSNet Asset Value(s)
18th Mar 202011:52 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.